Allison S. Thomas
Boston University
14 Papers
34 Citations
Allison S. Thomas is an academic researcher from Boston University. The author has contributed to research in topics: Antibody & Immunology. The author has an hindex of 5, co-authored 11 publications. Previous affiliations of Allison S. Thomas include George Washington University.
Chat about Author
Papers
Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.
Ross A. Pollack,R. Brad Jones,Mihaela Pertea,Katherine M. Bruner,Alyssa R. Martin,Allison S. Thomas,Adam A. Capoferri,Adam A. Capoferri,Subul A. Beg,Subul A. Beg,Szu-Han Huang,Sara Karandish,Haiping Hao,Eitan Halper-Stromberg,Patrick C. Yong,Colin Kovacs,Erika Benko,Robert F. Siliciano,Robert F. Siliciano,Ya Chi Ho +19 more
TL;DR: It is shown that defective proviruses can be transcribed into RNAs that are spliced and translated, and cells with defective major splice donors can be recognized by HIV-1-specific cytotoxic T lymphocytes (CTLs).
328
Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells
Szu-Han Huang,Y. Ren,Allison S. Thomas,Dora Chan,Stefanie Mueller,Adam R. Ward,Shabnum Patel,Shabnum Patel,Catherine M. Bollard,Catherine M. Bollard,Conrad Russell Y. Cruz,Conrad Russell Y. Cruz,Sara Karandish,Ronald Truong,Amanda B. Macedo,Alberto Bosque,Colin Kovacs,Erika Benko,Alicja Piechocka-Trocha,Hing C. Wong,Emily K. Jeng,Douglas F. Nixon,Ya Chi Ho,Robert F. Siliciano,Robert F. Siliciano,Bruce D. Walker,Bruce D. Walker,Bruce D. Walker,R. Brad Jones,R. Brad Jones +29 more
TL;DR: Treating CD4- T cells from ART-treated individuals with combinations of potent latency-reversing agents and autologous CD8+ T cells consistently reduced cell-associated HIV DNA, but failed to deplete replication-competent virus.
T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.
Allison S. Thomas,Kimberley Jones,Rajesh T. Gandhi,Rajesh T. Gandhi,Deborah McMahon,Joshua C. Cyktor,Dora Chan,Szu-Han Huang,Ronald Truong,Alberto Bosque,Amanda B. Macedo,Colin Kovacs,E. Benko,Joseph J. Eron,Ronald J. Bosch,Christina M. Lalama,Samuel J. Simmens,Bruce D. Walker,Bruce D. Walker,Bruce D. Walker,John W. Mellors,R. Brad Jones +21 more
TL;DR: The direct correlation between cell-associated HIV DNA levels and magnitudes of IFN-γ-producing Nef/Tat/Rev-specific T-cell responses suggests that ongoing Nef expression in ART-treated individuals drives preferential maintenance and/or expansion of T-cells reactive to this protein, implying sensing of infected cells by the immune system.
Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity.
Allison S. Thomas,Yvetane Moreau,Wenqing Jiang,John E. Isaac,Alexander Ewing,Laura F. White,Athena P. Kourtis,Manish Sagar +7 more
- 19 Oct 2021
TL;DR: In this article, the authors evaluated antibody-dependent cellular cytotoxicity (ADCC) present in pre-transmission infant and maternal plasma and breast milk (BM) against the contemporaneous maternal HIV-1 variants.
19
IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis
Rui André Saraiva Raposo,Miguel de Mulder Rougvie,Dominic Paquin-Proulx,Phillip M. Brailey,Vinicius D. Cabido,Paul M. Zdinak,Allison S. Thomas,Szu-Han Huang,Greta A. Beckerle,Richard B. Jones,Douglas F. Nixon +10 more
TL;DR: It is hypothesized that IFITM1 could mark natural reservoirs, identifying an immune target for killing of latently infected cells, and could be explored to develop clinical therapeutic approaches to effectively eradicate HIV-1.